Regulatory Landscape of Cannabis Warning Labels in US States with Legal Retail Nonmedical Cannabis, 2024.

IF 9.6 1区医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

American journal of public health Pub Date : 2024-11-01 DOI:10.2105/ajph.2024.307722

Caroline J Meek,Leah M Ranney,Sonia A Clark,Kristen L Jarman,Rachel Callanan,Sarah D Kowitt

{"title":"Regulatory Landscape of Cannabis Warning Labels in US States with Legal Retail Nonmedical Cannabis, 2024.","authors":"Caroline J Meek,Leah M Ranney,Sonia A Clark,Kristen L Jarman,Rachel Callanan,Sarah D Kowitt","doi":"10.2105/ajph.2024.307722","DOIUrl":null,"url":null,"abstract":"Objectives. To characterize regulatory practices related to nonmedical cannabis warning labels in states across the United States that have legalized retail nonmedical cannabis. Methods. In March 2024, we conducted a content analysis of regulations for nonmedical cannabis warning labels required on product packages in 20 states where, as of March 2024, adults could legally purchase nonmedical cannabis in retail environments. For each state, we examined requirements related to warning label content and characteristics. Results. Required warning label content and characteristics varied widely across states. Only 2 states required a warning about mental health risks (10%) and 2 states required a warning for high potency products on risk of psychosis (10%). No states required front-of-package warning placement, only 2 states required rotating warnings (10%), and 4 states required contrasting colors (20%). Warnings were often verbose (mean = 57 words), vague, and had small or no minimum font size. Conclusions. Opportunities exist for states to improve the alignment of their nonmedical cannabis warning label regulations with evidence that has been generated so far in cannabis effects, cannabis warning efficacy, and warning label design. (Am J Public Health. 2024;114(S8):S681-S684. https://doi.org/10.2105/AJPH.2024.307722).","PeriodicalId":7647,"journal":{"name":"American journal of public health","volume":null,"pages":null},"PeriodicalIF":9.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of public health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2105/ajph.2024.307722","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives. To characterize regulatory practices related to nonmedical cannabis warning labels in states across the United States that have legalized retail nonmedical cannabis. Methods. In March 2024, we conducted a content analysis of regulations for nonmedical cannabis warning labels required on product packages in 20 states where, as of March 2024, adults could legally purchase nonmedical cannabis in retail environments. For each state, we examined requirements related to warning label content and characteristics. Results. Required warning label content and characteristics varied widely across states. Only 2 states required a warning about mental health risks (10%) and 2 states required a warning for high potency products on risk of psychosis (10%). No states required front-of-package warning placement, only 2 states required rotating warnings (10%), and 4 states required contrasting colors (20%). Warnings were often verbose (mean = 57 words), vague, and had small or no minimum font size. Conclusions. Opportunities exist for states to improve the alignment of their nonmedical cannabis warning label regulations with evidence that has been generated so far in cannabis effects, cannabis warning efficacy, and warning label design. (Am J Public Health. 2024;114(S8):S681-S684. https://doi.org/10.2105/AJPH.2024.307722).

查看原文本刊更多论文

2024 年美国非药用大麻合法零售州大麻警示标签的监管情况。

目标。描述美国已实现非药用大麻零售合法化的各州与非药用大麻警示标签相关的监管做法。方法。2024 年 3 月，我们对 20 个州的产品包装上所需的非医用大麻警告标签法规进行了内容分析，截至 2024 年 3 月，这些州的成年人可以在零售环境中合法购买非医用大麻。我们对每个州的警告标签内容和特征的相关要求进行了研究。结果。各州要求的警告标签内容和特征差异很大。只有 2 个州要求警告精神健康风险（10%），2 个州要求警告高浓度产品的精神病风险（10%）。没有一个州要求在包装正面放置警告，只有 2 个州要求轮换警告（10%），4 个州要求使用对比色（20%）。警告内容往往冗长（平均=57个字）、含糊不清，字体较小或没有最小字体大小。结论。各州有机会改进其非医用大麻警示标签法规，使之与迄今为止在大麻效果、大麻警示效力和警示标签设计方面产生的证据相一致。(Am J Public Health.2024;114(S8):S681-S684. https://doi.org/10.2105/AJPH.2024.307722).

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of public health 医学-公共卫生、环境卫生与职业卫生

CiteScore

9.50

自引率

3.90%

发文量

1109

审稿时长

2-4 weeks

期刊介绍： The American Journal of Public Health (AJPH) is dedicated to publishing original work in research, research methods, and program evaluation within the field of public health. The journal's mission is to advance public health research, policy, practice, and education.